Immune responses to respiratory syncytial virus (RSV) vaccines tended to fall short in older people with weakened immunity, a ...
Cases begin rising across parts of the world after outbreak in China - India, Malaysia and Kazakhstan have began reporting ...
The U.S. Centers for Disease Control and Prevention (CDC) currently recommends that everyone 75 and older receive a single ...
A Massachusetts mother is warning other parents about the respiratory risks this season as her young has been hospitalized ...
Respiratory syncytial virus is the leading cause of hospitalization among U.S. infants. A vaccine, nirsevimab, can reduce the ...
The respiratory syncytial virus (RSV) vaccine may not protect older adults who are immunocompromised as much as their healthier peers, according to new research.
Approximately 40% of participants did not seroconvert or achieve a conservative neutralization threshold post-vaccination.
The first cases of Human Metapneumovirus (HMPV) in the country have been confirmed in two infants. The virus is prevalent ...
The study followed 38 immunocompromised adults, aged 64 to 72, who received either the Arexvy or Abrysvo RSV vaccine. Researchers found that people aged 60 and older who are immunocompromised ...
It parallels earlier work done at the center to better understand how the immune systems of people who are immunocompromised respond to vaccines against SARS-CoV-2, the virus that causes COVID-19.
In 38 immunocompromised persons who received either the RSVPreF3-AS01E (RSVA-AS01E; Arexvy) or RSVpreF (Abrysvo) vaccine, preF IgG antibody titers rose a median 4.21-fold by 4 weeks -- with 61% of ...
“We found that on average, older adults who are immunocompromised developed fewer antibodies against RSV following vaccination as compared with the very strong responses for healthy people over ...